Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Ranbaxy Ends Pact With Japanese Partner
by Jean-François Tremblay
December 14, 2009
| A version of this story appeared in
Volume 87, Issue 50
Ranbaxy Laboratories has agreed to sell partner Nihon Chemiphar its 50% stake in their Japanese joint venture, Nihon Pharmaceutical Industry. Chemiphar is a Japan-based developer and manufacturer of generic drugs. The companies did not explain whether the dissolution is linked to the 2008 acquisition of Ranbaxy by Daiichi Sankyo, one of Chemiphar’s competitors in Japan. To ensure a smooth transition, Ranbaxy will supply drugs made in India to Nihon for a limited time.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X